ImmuPharma (LON:IMM) Trading Up 19.3% – What’s Next?

ImmuPharma plc (LON:IMM)’s stock price was up 19.3% during trading on Friday . The company traded as high as GBX 12.95 ($0.18) and last traded at GBX 12.94 ($0.18). Approximately 16,757,994 shares changed hands during mid-day trading, an increase of 110% from the average daily volume of 7,961,430 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Performance

The firm has a market cap of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53. The business’s 50-day simple moving average is GBX 3.12 and its 200 day simple moving average is GBX 2.92.

ImmuPharma (LON:IMM) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.